Fresenius SE&Co. KGaA

This report does not constitute a rating action. Overview Key strengths Key risks Leading market positions within the Spanish and German hospital segments through Fresenius Helios, and intravenous (IV) generics and clinical nutrition products through Fresenius Kabi. Regulatory changes in the German hospital market, due to hospital reform and a potential change in the methodology used to determine the drug-related diagnosis inflator, could pressure profitability in the future. Presence across the entire patient care continuum--through hospitals, medications, and medical devices--with good geographic diversity and organic growth prospects. National tenders in China as part of the National Volume-Based Procurement (NVBP) and Provincial Volume-Based Procurement (PVBP) increase local competition and could weigh on Fresenius Kabi?s growth prospects. Positive free operating cash flow

...Fresenius delivered strong and resilient results through the third quarter (Q3) and first nine months of 2025. Group revenue was up 3% in Q3 2025 and 4% as of Sept. 30, and 6% on an organic basis. Both Fresenius Kabi and Fresenius Helios contributed to the growth. For the first nine months of 2025, Fresenius Kabi, which generates 38% of 2025 sales as of Sept. 30, showed revenue growth of 2% year on year supported by solid momentum in biopharma (reported revenue up 30% year on year as of Sept. 30, 2025), MedTech (4%), and clinical nutrition (stable revenue). In particular, for the first three quarters of 2025, biopharma revenue increased, driven by the ramp-up of Tocilizumab biosimilar Tyenne in Europe and North America. Fresenius Helios' revenue was up 6% year on year for the same period. In Germany, sales increased by 6% supported by hospital admission growth and positive pricing and, in Spain, the topline was up 5% year on year. At the same time, the group's reported EBIT margin was stable...

Full Report